Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Rapport Therapeutics Inc (RAPP)

Rapport Therapeutics Inc (RAPP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,371,684
  • Shares Outstanding, K 47,661
  • Annual Sales, $ 0 K
  • Annual Income, $ -78,310 K
  • EBIT $ -110 M
  • EBITDA $ -112 M
  • 60-Month Beta 1.63
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 2.67

Options Overview Details

View History
  • Implied Volatility 75.93% (-8.41%)
  • Historical Volatility 52.87%
  • IV Percentile 6%
  • IV Rank 2.12%
  • IV High 313.29% on 03/03/25
  • IV Low 70.79% on 12/05/25
  • Expected Move (DTE 6) 5.88 (19.43%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 11
  • Volume Avg (30-Day) 50
  • Put/Call OI Ratio 0.49
  • Today's Open Interest 1,443
  • Open Int (30-Day) 2,057
  • Expected Range 24.39 to 36.15

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.65
  • Number of Estimates 4
  • High Estimate -0.55
  • Low Estimate -0.82
  • Prior Year -0.57
  • Growth Rate Est. (year over year) -14.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
23.75 +27.45%
on 11/17/25
31.00 -2.35%
on 12/09/25
+5.10 (+20.26%)
since 11/12/25
3-Month
23.41 +29.30%
on 09/15/25
31.00 -2.35%
on 12/09/25
+6.51 (+27.40%)
since 09/12/25
52-Week
6.43 +370.76%
on 03/04/25
42.27 -28.39%
on 09/08/25
+11.26 (+59.23%)
since 12/12/24

Most Recent Stories

More News
Rapport Therapeutics Announces New Data and Post Hoc Analysis Demonstrating the Magnitude and Consistency of RAP-219’s Clinical Response in Patients with Focal Onset Seizures

Post-hoc analysis of RAP-219 Phase 2a data showed early onset of action and consistency of median response over the entire treatment period, along with consistent efficacy data regardless of patients’...

RAPP : 30.27 (+5.18%)
Rapport Therapeutics to Present New Phase 2a Data Analysis Further Characterizing RAP-219 in Focal Onset Seizures at 2025 American Epilepsy Society Annual Meeting

BOSTON and SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 30.27 (+5.18%)
Rapport Therapeutics Reports Third Quarter 2025 Financials and Provides Business Update

Positive topline results announced from Phase 2a clinical trial of RAP-219 in patients with focal onset seizures  Phase 2 trial of RAP-219 in bipolar mania enrolling patients and on track, with topline...

RAPP : 30.27 (+5.18%)
Rapport Therapeutics to Participate in Upcoming Investor Conferences

BOSTON and SAN DIEGO, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 30.27 (+5.18%)
Rapport Therapeutics to Participate in TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

BOSTON and SAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 30.27 (+5.18%)
Rapport Announces Pricing of Public Offering of Common Stock

BOSTON and SAN DIEGO, Sept. 09, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 30.27 (+5.18%)
Stocks Settle Higher as Bond Yields Fall and Chip Makers Climb

The S&P 500 Index ($SPX ) (SPY ) on Monday closed up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.46%. September E-mini...

APP : 670.67 (-6.46%)
CVS : 79.42 (-1.74%)
AVGO : 359.93 (-11.43%)
VZ : 40.89 (+1.67%)
ADI : 279.32 (-1.44%)
RAPP : 30.27 (+5.18%)
PINC : 28.26 (+0.32%)
$IUXX : 25,196.73 (-1.91%)
ASML : 1,080.85 (-3.74%)
ZNH26 : 112-055s (-0.25%)
ESZ25 : 6,830.75s (-1.11%)
T : 24.58 (+1.15%)
Rapport Announces Proposed Public Offering of Common Stock

BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery...

RAPP : 30.27 (+5.18%)
Stocks Supported by Hopes of Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) today is up +0.35%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.08%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.79%. September E-mini S&P futures (ESU25...

APP : 670.67 (-6.46%)
AVGO : 359.93 (-11.43%)
VZ : 40.89 (+1.67%)
RAPP : 30.27 (+5.18%)
PINC : 28.26 (+0.32%)
$IUXX : 25,196.73 (-1.91%)
ASML : 1,080.85 (-3.74%)
ZNH26 : 112-055s (-0.25%)
ESZ25 : 6,830.75s (-1.11%)
T : 24.58 (+1.15%)
TDG : 1,294.65 (-1.73%)
SBAC : 191.66 (-0.61%)
Stocks Mostly Higher on Fed Easing Prospects

The S&P 500 Index ($SPX ) (SPY ) today is up +0.17%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.23%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.58%. September E-mini S&P futures...

GOOGL : 309.29 (-1.01%)
AMAT : 259.21 (-4.04%)
APP : 670.67 (-6.46%)
AAPL : 278.28 (+0.09%)
AVGO : 359.93 (-11.43%)
VZ : 40.89 (+1.67%)
RAPP : 30.27 (+5.18%)
PINC : 28.26 (+0.32%)
$IUXX : 25,196.73 (-1.91%)
DUOL : 196.28 (-2.33%)
ASML : 1,080.85 (-3.74%)
ZNH26 : 112-055s (-0.25%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Rapport Therapeutics Inc. is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc. is based in BOSTON.

See More

Key Turning Points

3rd Resistance Point 33.64
2nd Resistance Point 32.07
1st Resistance Point 31.17
Last Price 30.27
1st Support Level 28.70
2nd Support Level 27.13
3rd Support Level 26.23

See More

52-Week High 42.27
Last Price 30.27
Fibonacci 61.8% 28.58
Fibonacci 50% 24.35
Fibonacci 38.2% 20.12
52-Week Low 6.43

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar